FDG-PET/CT in re-staging of patients with lymphoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The aim of this study was to evaluate the clinical significance of combined fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in patients with lymphoma, and to compare the FDG-PET/CT staging results with those of FDG-PET and CT alone. Twenty-seven patients were studied. Each patient had clinical follow-up for >12 months and entered complete follow-up evaluation. Patient-based evaluation showed a sensitivity of 78% for CT alone, 86% for FDG-PET alone, 93% for CT and FDG-PET read side by side, and 93% for combined FDG-PET/CT imaging. Region-based evaluation showed a sensitivity for regional lymph node involvement of 61%, 78%, 91% and 96% respectively. FDG-PET/CT imaging is superior to CT alone (P=0.02) and has additional benefit over FDG-PET alone due to exact anatomical localisation. We conclude that FDG-PET/CT imaging is accurate in re-staging lymphoma and offers advantages over separate FDG-PET and CT imaging.
- DeVita VT, Canellos GP. The lymphomas. Semin Hematol 1999; 36:84–94.
- Jotti G, Bonadonna G. Prognostic factors in Hodgkin’s disease; implications for modern treatment. Anticancer Res 1988; 8:749–760.
- Marshall WH Jr, Breiman RS, Harell GS, Glatstein E, Kaplan HS. Computed tomography of abdominal para-aortic lymph node disease: preliminary observation with a 6 second scanner. Am J Roentgenol 1977; 128:759–764.
- Van den Bossche B, Lambert B, de Winter F, Kolindou A, Dierckx RA, Noen L, van de Wiele C.18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 2002; 23:1079–1083. CrossRef
- Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631–1637.
- Maisey NR, Hill ME, Webb A, et al. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 36:200–206.
- Mikhaeel NG, Timothy AR, Hain SF, O’Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl 1):147–150.
- Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055–1063.
- Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22:434–442.
- de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8:57–60.
- Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.
- Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Prognostic value of pretransplant positron emission tomography using fluorine18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53–59. CrossRef
- Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13:1356–1363.
- Gambhir SSJ, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S–93S.
- Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, Nutt R, Meltzer CC, Villemagne V, Townsend DW. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000; 25:905–910.
- Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41:1369–1379.
- Townsend DW, Cherry SR. Combined anatomy and function: the path of true image fusion. Eur Radiol 2001; 11:1968–1974.
- Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002; 46:24–34.
- Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25:2046–2053. CrossRef
- Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, Bockisch A. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002; 179:1555–1560.
- Beyer T, Antoch G, Blodgett T, Freudenberg LS, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30:588–596.
- Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643–646.
- Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32:623–648.
- Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, Eddleston B. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol 1988; 6:940–946.
- Surbone A, Longo DL, DeVita VT, Ihde DC, Duffey PL, Jaffe ES, Solomon D, Hubbard SM, Young RC. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6:1832–1837.
- Naumann R, Vaic A, Beuthin-Baum B, Bredow J, Kropp J, Kittner T, Franke W, Ehnihger E. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001; 115:793–800. CrossRef
- FDG-PET/CT in re-staging of patients with lymphoma
European Journal of Nuclear Medicine and Molecular Imaging
Volume 31, Issue 3 , pp 325-329
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Clinic and Policlinic for Nuclear Medicine, University of Essen, Hufelandstrasse 55, 45122, Essen, Germany
- 2. Department of Radiology, University of Essen, Essen, Germany
- 3. Department of Internal Medicine (Cancer Research), University of Essen, Essen, Germany